Skip to content
← Holders

Great Point Partners LLC

What Great Point Partners LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1281446 · Filed Nov 16, 2026

Positions
45
Reported value
$418.5M
Opened
12
Closed
9
Other managers included
2

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$242.5M
    30 positions
  2. Dec 31, 2025$308.4M
    29 positions
  3. Mar 31, 2026$435.1M
    42 positions
  4. Jun 30, 2026$529.1M
    42 positions
  5. Sep 30, 2026$418.5M
    45 positions
SecuritySharesChangeValueOf portfolio
IBRXImmunityBio, Inc.Put option
3M±0%$28.3M6.8%
VERAVera Therapeutics, Inc.
808.7K+34.6%$26.1M6.2%
VORVor Biopharma Inc.
1.1M−33.7%$21.5M5.1%
AMLXAmylyx Pharmaceuticals, Inc.
700K±0%$20.4M4.9%
SGMTSagimet Biosciences Inc.
2M−3.4%$19.4M4.6%
DFTXDefinium Therapeutics, Inc.
508.7K+19.7%$19.4M4.6%
IONSIonis Pharmaceuticals Inc
420KNew$18.8M4.5%
GMABGenmab A/S
525KNew$18.7M4.5%
SLGLSol-Gel Technologies Ltd.
239.2K−12.8%$17.8M4.2%
ZURAZura Bio Ltd
4.1M−3.3%$17M4.1%
LBRXLB Pharmaceuticals Inc
410.4K+29.4%$15.8M3.8%
ABVXAbivax S.A.
155K−24.1%$15.3M3.7%
ANNXAnnexon, Inc.
3.5M±0%$14.8M3.5%
BLTEBelite Bio, Inc
75KNew$12.7M3%
EPRXEupraxia Pharmaceuticals Inc.
1.2M±0%$10.9M2.6%
NKTRNektar Therapeutics
175K±0%$10.6M2.5%
MLTXMoonLake Immunotherapeutics
855.8K±0%$10M2.4%
CLYMClimb Bio, Inc.
800K−20.0%$9.2M2.2%
ABCLAbCellera Biologics Inc.
600KNew$8.8M2.1%
NGNENeurogene Inc.
300K−14.8%$8.3M2%
CMPSCOMPASS Pathways plc
500KNew$6.2M1.5%
JATTJATT II Acquisition Corp.
500K±0%$5.6M1.3%
IFRXInflaRx N.V.
3M±0%$5.5M1.3%
RACCResearch Alliance Corp III
504.9KNew$5.5M1.3%
DRUGBright Minds Biosciences Inc.
109.6K±0%$5.5M1.3%
AMANAmanat Acquisition Corp.
500K±0%$5.3M1.3%
ALTAltimmune, Inc.
1.7M±0%$5M1.2%
JTTTJATT III Acquisition Corp
450KNew$5M1.2%
PHVSPharvaris N.V.Put option
150KNew$4.8M1.1%
SCYXScynexis Inc
944.3K±0%$4.7M1.1%
CGEMCullinan Therapeutics, Inc.
300K±0%$4.6M1.1%
CTNMContineum Therapeutics, Inc.Call option
300KNew$4M1%
HELPHelus Pharma Inc.
321KNew$3.9M0.9%
RZLTRezolute, Inc.
951.8K±0%$3.9M0.9%
IRDOpus Genetics, Inc.
776.9K−60.6%$3.8M0.9%
ELVNEnliven Therapeutics, Inc.
70K±0%$3.2M0.8%
RLMDRelmada Therapeutics, Inc.
842.1K±0%$3.2M0.8%
DBVTDBV Technologies S.A.
250K+59.3%$2.9M0.7%
EVMNEvommune, Inc.
325K±0%$2.7M0.6%
CTNMContineum Therapeutics, Inc.
186.2K−79.8%$2.5M0.6%
ORKAOruka Therapeutics, Inc.
24.6K−86.6%$2.1M0.5%
HUMAHumacyte, Inc.
3.8M±0%$1.9M0.5%
RNTXRein Therapeutics, Inc.
1.7M−35.4%$1.3M0.3%
RACDResearch Alliance Corp IV
106.4KNew$1.3M0.3%
ANNXAnnexon, Inc.Call option
97.3KNew$411.6K0.1%